Hematology/Oncology

Top Story

FDA grants breakthrough therapy designation to IMMU-132 for triple-negative breast cancer

February 8, 2016

The FDA granted breakthrough therapy designation to sacituzumab govitecan for the treatment of patients with triple-negative breast cancer who have failed at least two former therapies for metastatic disease, according to a press release from the drug’s manufacturer.

Sacituzumab govitecan (IMMU-132, Immunomedics) is developed by conjugating the moderately toxic drug, SN-38 — the active metabolite of irinotecan (Camptosar, Pfizer) — to an anti–Trop-2 antibody. The Trop-2 receptor is expressed by numerous solid cancers.

In the Journals

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

February 8, 2016
Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping” — to prevent…
Breaking News

Senate health committee considers seven biomedical innovation bills

February 8, 2016
The U.S. Senate Committee on Health, Education, Labor and Pensions will consider seven bipartisan bills on biomedical innovation tomorrow, Feb. 9, at the first of three…
In the Journals

PSA testing rates differ among urologists, PCPs

February 8, 2016
PSA testing rates have declined overall since the U.S. Preventive Services Task Force made a recommendation against the test, but these declines were greater among…
FDA News

FDA grants orphan drug designation to tazemetostat for treatment of malignant rhabdoid tumors

February 8, 2016
The FDA granted orphan drug status to tazemetostat for the treatment of malignant rhabdoid tumors, according to a press release from the agent’s manufacturer.The…
More News Headlines »
CME

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
At IssueVideo

VIDEO: Combination immunotherapy promising, but questions remain

February 2, 2016
More »
Featured
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Current Issues
View the Current Issue
HemOnc Today